Targeting antisense mitochondrial ncRNAs inhibits murine melanoma tumor growth and metastasis through reduction in survival and invasion factors
Artículo
Open/ Download
Publication date
2016Metadata
Show full item record
Cómo citar
Lobos González, Lorena
Cómo citar
Targeting antisense mitochondrial ncRNAs inhibits murine melanoma tumor growth and metastasis through reduction in survival and invasion factors
Author
- Lobos González, Lorena;
- Silva, Verónica;
- Araya, Mariela;
- Restovic, Franko;
- Echeñique, Javiera;
- Oliveira Cruz, Luciana;
- Fitzpatrick, Christopher;
- Briones, Macarena;
- Villegas, Jaime;
- Villota, Claudio;
- Vidaurre, Soledad;
- Borgna, Vincenzo;
- Socias, Miguel;
- Valenzuela, Sebastián;
- López, Constanza;
- Socias, Teresa;
- Varas, Manuel;
- Díaz, Jorge;
- Burzio, Luis O.;
- Burzio, Verónica A.;
Abstract
We reported that knockdown of the antisense noncoding mitochondrial RNAs (ASncmtRNAs) induces apoptotic death of several human tumor cell lines, but not normal cells, suggesting this approach for selective therapy against different types of cancer. In order to translate these results to a preclinical scenario, we characterized the murine noncoding mitochondrial RNAs (ncmtRNAs) and performed in vivo knockdown in syngeneic murine melanoma models. Mouse ncmtRNAs display structures similar to the human counterparts, including long double-stranded regions arising from the presence of inverted repeats. Knockdown of ASncmtRNAs with specific antisense oligonucleotides (ASO) reduces murine melanoma B16F10 cell proliferation and induces apoptosis in vitro through downregulation of pro-survival and metastasis markers, particularly survivin. For in vivo studies, subcutaneous B16F10 melanoma tumors in C57BL/6 mice were treated systemically with specific and control antisense oligonucleotides (ASO). For metastasis studies, tumors were resected, followed by systemic administration of ASOs and the presence of metastatic nodules in lungs and liver was assessed. Treatment with specific ASO inhibited tumor growth and metastasis after primary tumor resection. In a metastasis-only assay, mice inoculated intravenously with cells and treated with the same ASO displayed reduced number and size of melanoma nodules in the lungs, compared to controls. Our results suggest that ASncmtRNAs could be potent targets for melanoma therapy. To our knowledge, the ASncmtRNAs are the first potential non-nuclear targets for melanoma therapy.
Patrocinador
CONICYT, Chile
Fondecyt 1110835
1140345
Fondecyt 11090060
Fondecyt 1085210
Fondef D04I1338
Fondecyt 11140204
PAI 7812030019
CCTE-PFB16
Indexation
Artículo de publicación ISI
Quote Item
Oncotarget, Vol. 7, No. 36 Sept 2016
Collections
The following license files are associated with this item: